21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

24 November 2022 - BEAM Alliance

BEAM Alliance supported the Antimicrobial Resistance campaign within the Guardian and online

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

BEAM News
Member News
Events

Latest news of BEAM Alliance

07 December 2022 - BEAM Alliance

BEAM Alliance’s reaction to the ‘non-paper’ issued by 14 Member states on antimicrobial market incentives

BEAM Alliance calls for an open, evidence-based discussion on the best possible solutions to be implemented at the EU-level to…

24 November 2022 - BEAM Alliance

BEAM Alliance supported the Antimicrobial Resistance campaign within the Guardian and online

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

21 November 2022 - BEAM Alliance

BEAM Alliance: Building the right PULL incentive for Europe

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

25 November 2021 - BEAM Alliance

Antimicrobial Resistance Campaign 2021

Antimicrobial Resistance Campaign 2021. The needs of SMEs must be considered when reshaping the regulatory framework in AMR innovation.

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

page 1/6

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

31 January 2023 - Omnix Medical

Omnix Medical is pleased to announce the addition of two new peptide families – OMN50 and OMN70.

Omnix Medical is developing a promising pipeline of novel anti-infective agents based on a new approach of fighting infectious diseases,…

31 January 2023 - BioVersys AG

BioVersys announces first patient dosed in phase 2a clinical trial with BVL-GSK098

BVL-GSK098 is a small molecule developed from BioVersys’ award winning Transcriptional Regulatory Inhibitory Compounds (TRIC) platform in a successful collaboration…

11 January 2023 - Basilea

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and…

09 January 2023 - Spexis AG

Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound

Successful completion of the first-in-human clinical trial with novel class antibiotic murepavadin, delivered via the oral inhalation route (iMPV)

05 January 2023 - BioVersys AG

BioVersys extends of its Series C round to CHF 32.6 million with investment from the AMR Action Fund

We are proud that BioVersys was selected as the first European-based investment of the AMR Action Fund. This investment is…

29 December 2022 - AdjuTec Pharma AS

AdjuTec Pharma Attracts Public Funding to Optimize Drug Manufacturing

AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market.

page 1/47

Events

20 March 2023

BIO-Europe Spring 2023: Meet your next strategic partner at Europe’s largest springtime partnering event.

The annual BIO-Europe Spring® conference will bring together the life science community for global dealmaking in-person and digitally.

16 March 2023

7th AMR Conference

The AMR conference is the one-stop-shop for all AMR stakeholders from industry, SMEs, start-ups, big pharma, academia, clinics, regulatory bodies,…

21 February 2023

5th Bacteriophage Therapy Summit

Whether you’re at the forefront of the field or emerging into phage therapy for the first time, the 5th Bacteriophage…

24 January 2023

REVIVE Webinar: Delivery systems in antibacterial drug discovery

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…

09 January 2023

Biotech Showcase™ 2023—15th Annual International Partnering Conference

Biotech Showcase™ is an investor and networking conference devoted to providing private and micro-mid-cap biotechnology companies an opportunity to present…

13 December 2022

REVIVE Webinar: Influence of biological sex in infectious disease

REVIVE is a space for everybody with an interest in antimicrobial R&D.

22 November 2022

GARDP Webinar: Putting children first – Towards a better outcome for children and newborns with drug-resistant infections

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…

17 November 2022

Emerging Antimicrobials and Diagnostics in AMR 2022 (EADA 2022)

EADA 2022 welcomes presenters from startups, SMEs, multinationals, academia and research institutions active in the domain of antibiotics, antimicrobials, alternative…

08 November 2022

REVIVE Webinar: Regulatory aspects of balancing benefits and risks in the clinical development of antibiotics

REVIVE is a space for everybody with an interest in antimicrobial R&D.

page 1/15